Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer

D. Amadori, G. L. Frassineti, E. Flamini, F. Falcini, M. Maltoni, O. Nanni, A. Riccobon, C. Piccinini

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The action of high-dose medroxyprogesterone acetate (MPA) was studied by analysing the behaviour of colony-forming-unit granulocyte-macrophage (CFU-GM) during chemotherapy. 21 non-pretreated men with locally advanced carcinoma of the head and neck were randomised into two arms: A (11 patients) received three alternating cycles of cisplatin, 5-fluorouracil (CF)/cisplatin, methotrexate, bleomycin, vincristine and then CF every 4 weeks and B (10 patients) were treated with the same schedule plus 1000 mg per day of MPA. MPA was administered 14 days before the start of chemotherapy (day 0) and continued daily up to the 90th day. Bone marrow was harvested in arm A on days 0, +14 and +90, and in B, also on day -14. There was diverse CFU-GM behaviour in the two arms on the 14th day. These data support the hypothesis that the myeloprotective effect of MPA is due to induction of a mitotic rest in the stem cells, which protects them from drug action.

Original languageEnglish
Pages (from-to)1331-1334
Number of pages4
JournalEuropean Journal of Cancer
Volume28
Issue number8-9
DOIs
Publication statusPublished - 1992

Fingerprint

Medroxyprogesterone Acetate
Head and Neck Neoplasms
Cisplatin
Granulocyte-Macrophage Progenitor Cells
Arm
Fluorouracil
Drug Therapy
Bleomycin
Vincristine
Methotrexate
Appointments and Schedules
Neck
Stem Cells
Bone Marrow
Head
Carcinoma
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer. / Amadori, D.; Frassineti, G. L.; Flamini, E.; Falcini, F.; Maltoni, M.; Nanni, O.; Riccobon, A.; Piccinini, C.

In: European Journal of Cancer, Vol. 28, No. 8-9, 1992, p. 1331-1334.

Research output: Contribution to journalArticle

@article{a65da7f458314dd5964808e2c637a161,
title = "Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer",
abstract = "The action of high-dose medroxyprogesterone acetate (MPA) was studied by analysing the behaviour of colony-forming-unit granulocyte-macrophage (CFU-GM) during chemotherapy. 21 non-pretreated men with locally advanced carcinoma of the head and neck were randomised into two arms: A (11 patients) received three alternating cycles of cisplatin, 5-fluorouracil (CF)/cisplatin, methotrexate, bleomycin, vincristine and then CF every 4 weeks and B (10 patients) were treated with the same schedule plus 1000 mg per day of MPA. MPA was administered 14 days before the start of chemotherapy (day 0) and continued daily up to the 90th day. Bone marrow was harvested in arm A on days 0, +14 and +90, and in B, also on day -14. There was diverse CFU-GM behaviour in the two arms on the 14th day. These data support the hypothesis that the myeloprotective effect of MPA is due to induction of a mitotic rest in the stem cells, which protects them from drug action.",
author = "D. Amadori and Frassineti, {G. L.} and E. Flamini and F. Falcini and M. Maltoni and O. Nanni and A. Riccobon and C. Piccinini",
year = "1992",
doi = "10.1016/0959-8049(92)90511-Y",
language = "English",
volume = "28",
pages = "1331--1334",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "8-9",

}

TY - JOUR

T1 - Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer

AU - Amadori, D.

AU - Frassineti, G. L.

AU - Flamini, E.

AU - Falcini, F.

AU - Maltoni, M.

AU - Nanni, O.

AU - Riccobon, A.

AU - Piccinini, C.

PY - 1992

Y1 - 1992

N2 - The action of high-dose medroxyprogesterone acetate (MPA) was studied by analysing the behaviour of colony-forming-unit granulocyte-macrophage (CFU-GM) during chemotherapy. 21 non-pretreated men with locally advanced carcinoma of the head and neck were randomised into two arms: A (11 patients) received three alternating cycles of cisplatin, 5-fluorouracil (CF)/cisplatin, methotrexate, bleomycin, vincristine and then CF every 4 weeks and B (10 patients) were treated with the same schedule plus 1000 mg per day of MPA. MPA was administered 14 days before the start of chemotherapy (day 0) and continued daily up to the 90th day. Bone marrow was harvested in arm A on days 0, +14 and +90, and in B, also on day -14. There was diverse CFU-GM behaviour in the two arms on the 14th day. These data support the hypothesis that the myeloprotective effect of MPA is due to induction of a mitotic rest in the stem cells, which protects them from drug action.

AB - The action of high-dose medroxyprogesterone acetate (MPA) was studied by analysing the behaviour of colony-forming-unit granulocyte-macrophage (CFU-GM) during chemotherapy. 21 non-pretreated men with locally advanced carcinoma of the head and neck were randomised into two arms: A (11 patients) received three alternating cycles of cisplatin, 5-fluorouracil (CF)/cisplatin, methotrexate, bleomycin, vincristine and then CF every 4 weeks and B (10 patients) were treated with the same schedule plus 1000 mg per day of MPA. MPA was administered 14 days before the start of chemotherapy (day 0) and continued daily up to the 90th day. Bone marrow was harvested in arm A on days 0, +14 and +90, and in B, also on day -14. There was diverse CFU-GM behaviour in the two arms on the 14th day. These data support the hypothesis that the myeloprotective effect of MPA is due to induction of a mitotic rest in the stem cells, which protects them from drug action.

UR - http://www.scopus.com/inward/record.url?scp=0026740999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026740999&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(92)90511-Y

DO - 10.1016/0959-8049(92)90511-Y

M3 - Article

VL - 28

SP - 1331

EP - 1334

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 8-9

ER -